In vivo cell reprogramming

Ensoma

This company develops in vivo genomic medicines and vector delivery platforms to engineer blood and immune cells for patients with genetic diseases and cancer.

Encellin

The company develops an encapsulated cell replacement therapy to deliver living medicines for patients with endocrine disorders such as type 1 diabetes.

Stylus Medicine

This biotechnology company develops in vivo genetic medicines using engineered recombinases and lipid nanoparticles for patients with cancer, autoimmune and genetic diseases.

nChroma Bio

The company develops liver-targeted epigenetic editing therapies and non-viral delivery systems to treat patients with chronic hepatitis B and hepatitis D.

nChroma (formerly Chroma Medicine)

The company develops programmable epigenetic editing therapies and delivery technologies for patients with chronic hepatitis B and other genetic diseases.

NewLimit

This biotechnology company develops epigenetic reprogramming medicines to restore cellular function and treat age-related diseases for patients.

Spot Biosystems

This company develops non-viral gene therapy delivery platforms using extracellular vesicles to treat genetic diseases for pharmaceutical partners and healthcare providers.

CREATE Medicines

The company develops in vivo CAR therapies using an mRNA platform to treat patients with cancer, autoimmune diseases, and fibrosis.